In the exploratory NICHE study, among patients with early-stage CRC and preserved mismatch repair system (pMMR), only those with high pre-treatment CD8+PD-1+ T cell infiltration responded to neoadjuvant immunotherapy, while all patients with dMMR tumors responded [20]. Here, CD8A is linked to colorectal carcinoma.